- Home
- MOLN vs SGMO Comparison
MOLN vs SGMO Comparison
Compare MOLN & SGMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MOLN | SGMO |
|---|---|---|
| Founded | 2004 | 1995 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 144.0M | 141.2M |
| IPO Year | 2021 | 2000 |
Fundamental Metrics
Financial Performance| Metric | MOLN | SGMO |
|---|---|---|
| Price | $3.80 | $0.18 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $8.38 | $7.00 |
| AVG Volume (30 Days) | 2.0K | ★ 20.9M |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 10.20 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $36,567,000.00 |
| Revenue This Year | N/A | $107.15 |
| Revenue Next Year | $374.07 | $76.44 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 88.60 |
| 52 Week Low | $3.41 | $0.12 |
| 52 Week High | $5.36 | $0.77 |
Technical Indicators
Market Signals| Indicator | MOLN | SGMO |
|---|---|---|
| Relative Strength Index (RSI) | 34.58 | 37.98 |
| Support Level | $3.52 | N/A |
| Resistance Level | $3.97 | $0.55 |
| Average True Range (ATR) | 0.09 | 0.03 |
| MACD | -0.05 | -0.01 |
| Stochastic Oscillator | 11.11 | 34.48 |
Price Performance
Historical ComparisonAbout MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.
About SGMO Sangamo Therapeutics Inc.
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.